S&P 500   3,905.42 (-0.47%)
DOW   31,282.26 (-0.66%)
QQQ   291.75 (+0.21%)
AAPL   138.24 (-1.83%)
MSFT   255.08 (+0.39%)
FB   192.82 (+0.30%)
GOOGL   2,221.70 (-0.73%)
AMZN   2,165.27 (+1.07%)
TSLA   713.52 (+0.52%)
NVDA   173.57 (+2.47%)
BABA   87.94 (+0.72%)
NIO   16.69 (+5.43%)
AMD   97.95 (+1.73%)
CGC   5.93 (+6.08%)
MU   70.06 (-1.39%)
T   20.19 (-0.20%)
GE   76.11 (+1.21%)
F   13.04 (+2.03%)
DIS   103.83 (-0.45%)
AMC   13.10 (+2.66%)
PFE   50.69 (+0.58%)
PYPL   81.63 (+5.77%)
NFLX   184.59 (+4.18%)
S&P 500   3,905.42 (-0.47%)
DOW   31,282.26 (-0.66%)
QQQ   291.75 (+0.21%)
AAPL   138.24 (-1.83%)
MSFT   255.08 (+0.39%)
FB   192.82 (+0.30%)
GOOGL   2,221.70 (-0.73%)
AMZN   2,165.27 (+1.07%)
TSLA   713.52 (+0.52%)
NVDA   173.57 (+2.47%)
BABA   87.94 (+0.72%)
NIO   16.69 (+5.43%)
AMD   97.95 (+1.73%)
CGC   5.93 (+6.08%)
MU   70.06 (-1.39%)
T   20.19 (-0.20%)
GE   76.11 (+1.21%)
F   13.04 (+2.03%)
DIS   103.83 (-0.45%)
AMC   13.10 (+2.66%)
PFE   50.69 (+0.58%)
PYPL   81.63 (+5.77%)
NFLX   184.59 (+4.18%)
S&P 500   3,905.42 (-0.47%)
DOW   31,282.26 (-0.66%)
QQQ   291.75 (+0.21%)
AAPL   138.24 (-1.83%)
MSFT   255.08 (+0.39%)
FB   192.82 (+0.30%)
GOOGL   2,221.70 (-0.73%)
AMZN   2,165.27 (+1.07%)
TSLA   713.52 (+0.52%)
NVDA   173.57 (+2.47%)
BABA   87.94 (+0.72%)
NIO   16.69 (+5.43%)
AMD   97.95 (+1.73%)
CGC   5.93 (+6.08%)
MU   70.06 (-1.39%)
T   20.19 (-0.20%)
GE   76.11 (+1.21%)
F   13.04 (+2.03%)
DIS   103.83 (-0.45%)
AMC   13.10 (+2.66%)
PFE   50.69 (+0.58%)
PYPL   81.63 (+5.77%)
NFLX   184.59 (+4.18%)
S&P 500   3,905.42 (-0.47%)
DOW   31,282.26 (-0.66%)
QQQ   291.75 (+0.21%)
AAPL   138.24 (-1.83%)
MSFT   255.08 (+0.39%)
FB   192.82 (+0.30%)
GOOGL   2,221.70 (-0.73%)
AMZN   2,165.27 (+1.07%)
TSLA   713.52 (+0.52%)
NVDA   173.57 (+2.47%)
BABA   87.94 (+0.72%)
NIO   16.69 (+5.43%)
AMD   97.95 (+1.73%)
CGC   5.93 (+6.08%)
MU   70.06 (-1.39%)
T   20.19 (-0.20%)
GE   76.11 (+1.21%)
F   13.04 (+2.03%)
DIS   103.83 (-0.45%)
AMC   13.10 (+2.66%)
PFE   50.69 (+0.58%)
PYPL   81.63 (+5.77%)
NFLX   184.59 (+4.18%)
NASDAQ:ARVN

Arvinas (ARVN) Stock Forecast, Price & News

$44.18
+1.34 (+3.13%)
(As of 05/19/2022 03:21 PM ET)
Add
Compare
Today's Range
$42.11
$44.69
50-Day Range
$38.41
$74.24
52-Week Range
$37.41
$108.46
Volume
10,981 shs
Average Volume
642,242 shs
Market Capitalization
$2.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.05
30 days | 90 days | 365 days | Advanced Chart
Receive ARVN News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

Arvinas logo

About Arvinas

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Headlines

Arvinas (NASDAQ:ARVN) Downgraded to "Neutral" at Wedbush
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
280
Year Founded
N/A

Sales & Book Value

Annual Sales
$46.70 million
Book Value
$13.60 per share

Profitability

Net Income
$-191 million
Net Margins
-326.72%
Pretax Margin
-319.77%

Debt

Price-To-Earnings

Miscellaneous

Free Float
49,737,000
Market Cap
$2.35 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/19/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.30 out of 5 stars

Medical Sector

276th out of 1,418 stocks

Pharmaceutical Preparations Industry

105th out of 677 stocks

Analyst Opinion: 4.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -













Arvinas (NASDAQ:ARVN) Frequently Asked Questions

Is Arvinas a buy right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 2 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arvinas stock.
View analyst ratings for Arvinas
or view top-rated stocks.

When is Arvinas' next earnings date?

Arvinas is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Arvinas
.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) announced its earnings results on Thursday, May, 5th. The company reported ($1.20) EPS for the quarter, missing the consensus estimate of ($0.91) by $0.29. The business had revenue of $24.20 million for the quarter, compared to analysts' expectations of $25.51 million. Arvinas had a negative trailing twelve-month return on equity of 29.38% and a negative net margin of 326.72%. The firm's quarterly revenue was up 340.0% on a year-over-year basis.
View Arvinas' earnings history
.

What price target have analysts set for ARVN?

19 equities research analysts have issued 12 month price targets for Arvinas' stock. Their forecasts range from $43.00 to $170.00. On average, they expect Arvinas' share price to reach $108.71 in the next year. This suggests a possible upside of 145.0% from the stock's current price.
View analysts' price targets for Arvinas
or view top-rated stocks among Wall Street analysts.

Who are Arvinas' key executives?
Arvinas' management team includes the following people:
  • Dr. John G. Houston Ph.D., CEO, Pres & Director (Age 62, Pay $1.07M)
  • Mr. Sean A. Cassidy CPA, CPA, M.B.A., CFO & Treasurer (Age 52, Pay $667.73k) (LinkedIn Profile)
  • Dr. Ian Taylor Ph.D., Chief Scientific Officer (Age 59, Pay $686.8k)
  • Dr. Ronald A. Peck, Chief Medical Officer (LinkedIn Profile)
  • Mr. Jeff Boyle, VP of Investor Relations
  • Mr. Matthew Batters J.D., Gen. Counsel (Age 46)
  • Dr. Randy Teel Ph.D., Sr. VP of Corp. & Bus. Devel. (Age 43)
  • Mr. Steve Weiss, VP of HR (Age 53)
  • Dr. John A. Grosso Ph.D., Sr. VP of R&D Technical Operations (Age 65)
  • Ms. Angela M. Cacace Ph.D., Sr. VP of Neuroscience & Platform Biology (Age 54)
What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.57%), BlackRock Inc. (6.63%), Bellevue Group AG (4.10%), JPMorgan Chase & Co. (3.54%), Gilder Gagnon Howe & Co. LLC (2.56%) and State Street Corp (1.92%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon.
View institutional ownership trends for Arvinas
.

Which institutional investors are selling Arvinas stock?

ARVN stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Ally Bridge Group NY LLC, Emerald Mutual Fund Advisers Trust, Frontier Capital Management Co. LLC, Dimensional Fund Advisors LP, Bellevue Group AG, Candriam Luxembourg S.C.A., and Emerald Advisers LLC. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, and Timothy M Shannon.
View insider buying and selling activity for Arvinas
or view top insider-selling stocks.

Which institutional investors are buying Arvinas stock?

ARVN stock was bought by a variety of institutional investors in the last quarter, including Frazier Life Sciences Management L.P., Paradigm Biocapital Advisors LP, Wellington Management Group LLP, UBS Group AG, American Century Companies Inc., Invesco Ltd., State Street Corp, and Vanguard Group Inc.. Company insiders that have bought Arvinas stock in the last two years include Liam Ratcliffe, and Timothy M Shannon.
View insider buying and selling activity for Arvinas
or or view top insider-buying stocks.

How do I buy shares of Arvinas?

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $44.37.

How much money does Arvinas make?

Arvinas has a market capitalization of $2.36 billion and generates $46.70 million in revenue each year. The company earns $-191 million in net income (profit) each year or ($4.170010) on an earnings per share basis.

How many employees does Arvinas have?

Arvinas employs 280 workers across the globe.

What is Arvinas' official website?

The official website for Arvinas is www.arvinas.com.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at (203) 535-1456 or via email at [email protected].

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.